In a Phase 1b/2a trial for lymphoma and cytokine release syndrome, the first group's dose-limiting toxicity observation ...

Monitoring and analyzing gut microbes may help predict how myeloma patients will respond to CAR T-cell therapy, research ...

Over 80% of patients with relapsed/refractory multiple myeloma responded to anti-GPRC5D CAR T-cell therapy after failure of anti-BCMA CAR T-cell therapy. The investigational therapy showed superior ...

The Jackson Laboratory has developed a new platform to provide a fast, accurate and reliable method for screening novel immunotherapy treatments for efficacy and cytokine release syndrome.

In a live virtual event, Attaya Suvannasankha, MD, discussed the MajesTEC-1 trial of teclistamab and approaches to mitigation ...

Axi-cel, tisa-cel, and brexu-cel were found comparable to other cellular therapy experiences for patients with B-cell ...

Mark Litzow, MD, discusses the challenges of using immunotherapy for the treatment of acute lymphoblastic leukemia.

Imdelltra is associated with improvement in overall survival compared to local standard-of-care chemotherapy among patients with small cell lung cancer.

MONMOUTH JUNCTION, N.J., March 20, 2017 /PRNewswire/ -- CytoSorbents Corporation (NASDAQ: CTSO), a critical care immunotherapy leader commercializing its flagship CytoSorb® blood filter to treat ...